Mirabegron: β 3 -Adrenergic Receptor Agonist for the Treatment of Overactive Bladder

Abstract

Spanish

French

OBJECTIVE

To review the place in therapy of mirabegron, a new oral β₃-adrenergic receptor agonist, for the treatment of overactive bladder (OAB).

DATA SOURCES

A literature search of MEDLINE and MEDLINE In-Process & Other Non-Indexed Citations Databases (1996-April 2013) was conducted using the key words mirabegron, receptor, adrenergic, beta-3; adrenergic beta-3 receptor; beta-3 receptor, and overactive bladder; urinary bladder; overactive. All published articles regarding mirabegron were included. References of selected articles, data from poster presentations, and abstract publications were additionally reviewed.

STUDY SELECTION AND DATA EXTRACTION

Available English-language data from reviews, abstracts, presentations, and clinical trials of mirabegron in humans were reviewed; relevant clinical data were selected and included.

DATA SYNTHESIS

Mirabegron is the newest option for treatment of OAB with symptoms of urge incontinence. As a β₃-receptor agonist, it reduces bladder muscle contractions. In two 12-week, randomized, double-blind, placebo-controlled Phase 3 studies, mirabegron significantly reduced the number of incontinence episodes per 24 hours from baseline (−1.47, −1.63, and −1.13; p < 0.05; and −1.57, −1.46, and −1.17; p < 0.05; all values for mirabegron 50 mg, 100 mg, and placebo). Micturitions per 24 hours were also reduced from baseline (−1.66, −1.75, and −1.05; p < 0.05; and −1.93, −1.77, and −1.34; p < 0.05; all values for mirabegron 50 mg, 100 mg, and placebo). A 12-month trial found mirabegron to have a safety and efficacy profile similar to that of tolterodine.

CONCLUSIONS

Treatment of OAB initially includes lifestyle and nonpharmacologic intervention; for patients with persistent symptoms despite these treatments, drug therapy represents a next-step approach for symptom control. Mirabegron alleviates symptoms of OAB while having a mechanism of action that provides an alternative for patients who are intolerant of or who have contraindications to anticholinergic agents. The place in therapy of mirabegron relative to anticholinergics in the treatment of urge incontinence has not yet been established.

Get full access to this article

View all access options for this article.

References

1. Abrams

, Artibani

, Cardozo

, Reviewing the ICS 2002 terminology report: the ongoing debate. Neurourol Urodyn 2009; 28: 287.

2. Irwin

, Kopp

, Agatep

, Worldwide prevalence estimates of lower urinary tract symptoms, overactive bladder, urinary incontinence and bladder outlet obstruction. BJU Int 2011; 108: 1132–8.

3. Sexton

, Coyne

, Thompson

, Prevalence and effect on health-related quality of life of overactive bladder in older Americans: results from the epidemiology of lower urinary tract symptoms study. J Am Geriatr Soc 2011; 59: 1465–70.

4. Ouslander

. Management of overactive bladder. N Engl J Med 2004; 250: 786–99.

5. Staskin

. Overactive bladder in the elderly: a guide to pharmacological management. Drugs Aging 2005; 22: 1013–28.

6. Thüroff

, Abrams

, Andersson

, EAU guidelines on urinary incontinence. Eur Urol 2011; 59: 387–400.

7. Package insert. Enablex (Darifenacin). Stein, Switzerland. Novartis Pharma Stein AG, March 2012.

8. Package insert. Toviaz (fesoterodine). New York, NY: Pfizer Labs, August 2012.

9. Package insert. Ditropan (oxybutynin). Mountain View, CA: Alza Corporation, February 2008.

10.

10. Package insert. Vesicare (solifenacin). Norman, OK: Astellas Pharma Technologies, August 2012.

11.

11. Package insert. Detrol (dolterodine). New York, NY: Pfizer, March 2008.

12.

12. Package insert. Sanctura (trospium). Irvine, CA: Allergan Inc, July 2012.

13.

13. Package insert. Myrbetriq (mirabegron). Norman, OK: Astellas Pharma Technologies, Inc., June 2012.

14.

14. Andersson

, Arner

. Urinary bladder contraction and relaxation: physiology and pathophysiology. Physiol Rev 2004; 84: 935–86.

15.

15. Michel

, Vrydag

. β₁-, β₂- and β-adrenoceptors in the urinary bladder, urethra, and prostate. Br J Pharmacol 2006; 147: S88–119.

16.

16. Takasu

, Ukai

, Sato

, Effect of (R)-2-(2-aminothiazol-4-yl)-4′-{2-(2-hydroxy-2-phenylethyl)amino]ethyl} acetanilide (YM178), a novel selective B3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 2007: 321;642–7.

17.

17. Eltink

, Lee

, Schaddelee

, Single dose pharmacokinetics and absolute bioavailability of mirabegron, a B3-adrenoceptor agonist for treatment of overactive bladder. Int J Clin Pharmacol Ther 2012; 50: 838–50.

18.

18. van Gelderen

, Li

, Meijer

, An exploratory comparison of the single dose pharmacokinetics of the B3-adrenoceptor agonist mirabegron in healthy CYP2D6 poor and extensive metabolizers (abstract). Clin Pharmacol Ther 2009; 85: S88.

19.

19. Dickinson

, Lewand

, Sawamoto

, Effect of renal or hepatic impairment on the pharmacokinetics of mirabegron. Clin Drug Investig 2013; 33: 11–23.

20.

20. Chapple

, Amarenco

, López Aramburu

, Proof-of-concept study: mirabegron, a new therapy for overactive bladder. Neurol Urodyn. Epub February 19, 2013. doi: 10.1002/nau.22373

21.

21. Chapple

, Wyndaele

, Van Kerrebroeck

, Dose-ranging study of once-daily mirabegron (YM178), a novel selective β₃-adrenoceptor agonist in patients with overactive bladder (OAB) (abstract). Presented at: 25th Annual European Association of Urology; April 19, 2010; Barcelona, Spain.

22.

22. A randomized, double-blind, parallel group, placebo and active controlled, multi-center study to assess the efficacy and safety of the beta-3 agonist YM178 in subjects with symptoms of overactive bladder (SCORPIO). NCT00689104. http://clinicaltrials.gov/ct2/show/NCT00689104?term=nct00689104&rank=1 (accessed 2011 Sept 20).

23.

23. Khullar

, Cambronero

, Stroeberg

, The efficacy and tolerability of mirabegron, a potent and selective B3-adrenoceptor agonist, compared with placebo and tolterodine slow release in patients with overactive bladder-results from a European-Australian phase III trial (abstract). Presented at: 41st Annual Meeting of the International Continence Society, Glasgow, United Kingdom, August-September 2011.

24.

24. Khullar

, Amaernco

, Angulo

, Efficacy and tolerability of mirabegron, a β₃-adrenoceptor agonist, in patients with overactive bladder: results from a randomized European-Australian phase 3 trial. Eur Urol 2013; 63: 283–95.

25.

25. A phase III, randomized, double-blind, parallel group, placebo controlled, multi-center study to assess the efficacy and safety of the beta-3 agonist YM178 in subjects with symptoms of overactive bladder (ARIES). NCT00662909. http://clinicaltrials.gov/ct2/show/NCT00662909?term=mirabegron&rank=17 (accessed 2013 Jan 20).

26.

26. Nitti

, Herschorn

, Auerbach

, The selective beta-3 adrenoreceptor agonist mirabegron is effective and well tolerated in patients with overactive bladder syndrome (abstract). J Urol 2011; 185: e783–4.

27.

27. Nitti

, Auerbach

, Martin

, Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 2013; 189: 1388–95.

28.

28. A randomized, double-blind, parallel group, active controlled, multi-center long-term study to assess the safety and efficacy of the beta-3 agonist YM178 in subjects with symptoms of overactive bladder. NCT00688688. http://clinicaltrials.gov/ct2/show/NCT00688688?term=mirabegron&rank=20 (accessed 2013 Jan 20).

29.

29. Chapple

, Kaplan

, Mitcheson

, Randomised, double-blind, active controlled phase III study to assess the long-term safety and efficacy of mirabegron in overactive bladder (OAB) (abstract). Eur Urol Suppl 2012; 11: e683.

30.

30. Chapple

, Kaplan

, Mitcheson

, Randomized double-blind, active-controlled phase 3 study to assess 12-month safety and efficacy of mirabegron, a β₃-adrenoceptor agonist, in overactive bladder. Eur Urol 2013; 63: 296–305.

31.

31. A study to evaluate the efficacy, safety and tolerability of mirabegron and solifenacin alone and in combination for the treatment of overactive bladder (SYMPHONY). NCT01340027. http://clinicaltrials.gov/ct2/show/NCT01340027?term=mirabegron&rank=7 (accessed 2013 Jan 15.

32.

32. Malik

, van Gelderen

, Lee

. Proarrhythmic safety of repeat disease of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study. Clin Pharmacol Ther 2012; 92: 696–706.

33.

33. US Food and Drug Administration. Summary of safety and efficacy as basis for Advisory Committee briefing document for mirabegron, 5 April 2012. Division of Reproductive and Urologic Products, Office of New Drugs Center for Drug Evaluation and Research of Food and Drug Administration. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ (accessed 2013 Mar 1).

34.

34. Krauwinkel

, van Gelderen

, Groen

. An open-label, one sequence crossover study to evaluate the effect of multiple doses of mirabegron on the pharmacokinetics of the CYP2D6 substrate desipramine in healthy subjects (abstract). Presented at: Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; March 17–20, 2010; Atlanta, GA.

35.

35. Novara

, Galfano

, Secco

, A systematic review and meta-analysis of randomized controlled trials with antimuscarinic drugs for overactive bladder. Eur Urol 2008; 54: 740–63.

36.

36. AmerisourceBergen Drug Wholesaler. www.amerisourcebergen.com/abc (accessed 2013 Feb 27).